Search

Displaying results 1961 - 1970 of 4539 in total
  1. Drug

    Forigerimod

    go.drugbank.com/drugs/DB12490
    Investigational

    Forigerimod is under investigation for the treatment of Lupus Erythematosus, Systemic.

    Categories: Ribonucleoprotein, U1 Small Nuclear
  2. Drug

    Tirbanibulin

    go.drugbank.com/drugs/DB06137
    ApprovedInvestigational

    [A225726] On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand name Klisyri. … [L27806] Actinic keratosis is a chronic condition characterized by lesions, which can potentially transform into invasive squamous cell carcinoma with a risk of 1% over 10 years.

  3. Drug

    Quinacrine

    go.drugbank.com/drugs/DB01103
    Investigational

    An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years.

  4. Drug

    Aminocaproic acid

    go.drugbank.com/drugs/DB00513
    ApprovedInvestigational

    An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.

  5. Drug

    Iopamidol

    go.drugbank.com/drugs/DB08947
    ApprovedInvestigational

    Iopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.

  6. Drug

    Sparsentan

    go.drugbank.com/drugs/DB12548
    ApprovedInvestigational

    [L45300] On April 24, 2024, sparsentan was granted conditional marketing authorization by the European Commission for the treatment of adults with primary IgAN.[L51559] … [A257330,L45300] Sparsentan is first in its class and orally active, and was created by merging the structural elements of [irbesartan], an AT<sub>1</sub>R antagonist, and biphenylsulfonamide, an ET<sub

  7. Drug

    Allogeneic processed thymus tissue

    go.drugbank.com/drugs/DB16736
    Approved

    [L38929] Congenital athymia is a rare condition that leads to the absence of a thymus at birth and a high premature mortality rate, with patients typically dying by age two or three. … Allogeneic processed thymus tissue implantation works by migrating the recipient’s bone marrow-derived stem cells to the implanted cultured thymus tissue that develops immunocompetent naïve T cells.

  8. Drug

    Pyridostigmine

    go.drugbank.com/drugs/DB00545
    ApprovedInvestigational

    By inhibiting the breakdown of acetylcholine in the neuromuscular junction, they increase signalling and relieve symptoms.

  9. Drug

    Colistin

    go.drugbank.com/drugs/DB00803
    ApprovedInvestigational

    Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.

  10. Drug

    CYT-6091

    go.drugbank.com/drugs/DB05991
    Experimental

    CYT-6091 (Aurimune) is an investigational small molecule made up of recombinant human tumor necrosis factor alpha (rhTNF) and thiolyated polyethylene glycol bound to the surface of 27 nm colloidal gold